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Abstract 
This is a rare case of new onset Kaposi sarcoma in an HIV-infected man on antiretroviral treatment 
since primary HIV infection, with normal CD4+ cell count and suppressed viral load. The presentation 
questions the general understanding of Kaposi sarcoma as an AIDS-defining disease occurring 
predominantly in severely immunocompromised HIV-infected patients. 
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Case Report 
A 45 year old HIV-infected Caucasian man presented with an acute onset of a dark patchy skin lesion 
on his left foot (figure 1A) and a smaller dark papule on his penis (figure 1B). The painless lesions had 
developed within a few days.  He otherwise felt healthy and denied further symptoms. He had neither 
engaged in risky sexual behavior nor had he traveled recently. On physical examination no other 
physical abnormalities were seen. 
The patient is a MSM (men who have sex with men) and was diagnosed with primary HIV-1 infection 
in April 2009. At that time, he presented with symptoms of an acute retroviral syndrome, had a 
negative HIV screening test in November 2008 and the HIV Western Blot was positive for 3 of 5 
bands in the presence of a detectable p24 antigen. His baseline CD4+ cell count was 512/ul with a 
viral load of 4 million HIV-1 RNA copies/ml of plasma. He was immediately started on early 
antiretroviral treatment (ART) consisting of ritonavir-boosted darunavir combined with tenofovir and 
emtricitabine as part of the Zurich Primary HIV Infection Study1. Under antiretroviral therapy the 
patient's CD4+ cell count remained stably above 500/ul until today (range: 606/ul – 1002/ul, 29%-
34%). His viral load has been consistently undetectable (< 20 HIV-1 RNA copies/ml of plasma) for 
more than four years.  
As HIV-associated Kaposi sarcoma (KS) was suspected, skin biopsy of the lesion on his left foot was 
performed. The histology showed a dermal tumor consisting of spindle cells with some irregular 
vessel lumina formation, as well as plasma cells and erythrocyte extravasates in the tumoral stroma 
yielding the diagnosis of KS (Figure 2A). Immunohistochemistry proved the lymph vessel origin of the 
tumor by showing positivity for the lymph vessel marker d2-40. Further HHV-8 immunochemistry 
staining was positive in the spindle cells (Figure 2B), thus confirming the histological diagnosis.  
Based on its clinical aspect, the genital lesion was considered to be KS as well. Laboratory results 
showed normal C-reactive protein, blood count, liver and kidney function. Syphilis was ruled out by 
serology. The HIV-1 viral load was fully suppressed and his CD4+ cell count measured 620/ul (30%). 
Differentiation of T-cells showed increased expression of immune activation markers such as 
increased CD4/38 of 25/ul (normal: 4-22/ul) and CD8 HLA-DR of 135/ul (normal: 6-108/ul). Human 
Herpes Virus 8 (HHV-8) serologies and PCR were performed retrospectively from a blood-sample 
collected in April 2009 when the patient was first diagnosed with primary HIV-1 infection.  The 
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immunofluorescence assay revealed IgG antibodies against latent and lytic antigens in both samples, 
while IgM was negative, reflecting former HHV-8 infection. The HHV-8 PCR was negative in April 
2009 but showed 593 copies/ml of plasma at the onset of KS. To screen for possible further organ 
involvement gastrooesophagoduodenoscopy and colonoscopy were done, both showing no visceral 
lesions. A chest X-ray was normal as well. The patient’s current ART consisting of ritonavir-boosted 
darunavir combined with tenofovir and emtricitabine was continued.  After visceral KS had been ruled 
out, the lesion on the left foot was treated locally with cryotherapy. The genital lesion disappeared 
spontaneously after 8 weeks and repeat HHV-8 PCR was negative. The patient continues to be seen 
at our hospital regularly and is doing well at 6 months. The lesion on his right foot has healed 
completely. No further lesions have appeared in the meantime. He remains stably on ART with 
suppressed viral load and high CD4+ cell count.  
 
KS is considered an AIDS-defining neoplastic disease in HIV-infected patients_ENREF_2 and is 
caused by HHV-8. The vascular nodules of the angioproliferative tumor appear on the skin, mucous 
membranes and rarely in visceral organs (especially GI tract, lungs). Lymph node involvement is 
common. Clinical findings range from single or multiple skin lesions as seen in our case to vastly 
disseminated disease. Diagnosis is based on the clinical aspect of the lesion and the biopsy, which 
histologically shows a proliferation of spindle cells and endothelial cells, extravasation of red blood 
cells and hemosiderin-laden macrophages_ENREF_2. The development of KS in HIV-infected 
patients has historically been associated with low CD4+ cell counts (usually <200/ul) and the absence 
of ART. While KS was common in HIV-infected patients in the 1980s and 1990s, occurring in up to 
67% of patients diagnosed with HIV2, today it is rarely seen in countries with widespread distribution 
of effective ART3. Most patients who develop KS while on ART began treatment with low CD4+ cell 
counts and develop KS within the first 6 months since initiation of ART4.  A retrospective study by 
Daly et al aimed to investigate the characteristics of HIV-infected patients with CD4+ cell counts of 
>300 cells/ul and the presence of histologically confirmed KS5. Of the 23 cases described, seven 
(30%) presented with new onset KS while showing CD4+ cell counts >300/ul. All of the cases were 
MSM with a median age of 39 years (range 26-66 years) and only two of the patients were on ART at 
the time of diagnosis. This last fact prompts the authors to rule out immune reconstitution through 
ART as the sole cause of new onset KS in patients with high CD4+ cell counts. Crum-Cianflone et al. 
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evaluated longitudinal rates of Kaposi sarcoma and trends in CD4+ cell counts during the HIV 
epidemic (1985 – 2008)6. The group was able to demonstrate an increase of the proportion of KS 
cases in patients with higher CD4+ cell counts (> 350/µl) in a setting with widespread access to ART, 
which further highlighted the importance that clinicians should be aware of the occurrence of Kaposi’s 
sarcoma despite robust CD4+ cell counts. 
HHV-8 also referred to as Kaposi sarcoma-associated Herpes virus (KSHV) was identified in 1994 as 
the etiological agent of KS7. HHV-8 infection is necessary but not sufficient for the development of KS. 
HIV coinfection and immunosuppression significantly increase an HHV-8 seropositive patient's risk of 
developing a KS8. As other Herpes viruses it is transmitted through close person-to-person contact 
and establishes persistent infection. We were able to show a sudden and transient HHV-8 viremia in 
our patient at the time of onset of KS. Since the blood sample collected in 2009 already revealed 
seropositivity, a primary HHV-8 infection could be ruled out at the onset of disease. Sullivan et al. 
found a HHV-8 seropositivity rate of 69–75% in MSM in Switzerland without KS, suggesting 
widespread exposure to this virus in Swiss MSM9. We conclude that viral reactivation of unknown 
origin most likely contributed to the development of new onset KS in our patient. A further possible 
explanation for the patient’s transient HHV-8 viremia could be superinfection with a different HHV-8 
strain. Beyari et al were able to demonstrate multiple HHV-8 infection in a study population from 
Malawi10. Whether multiple HHV-8 carriage reflects simultaneous coinfection with more than one 
strain or superinfection remains unclear though. Most likely both options are possible. 
 
So far, defined staging guidelines for KS do not exist. Most management recommendations by clinical 
HIV societies do not include routine staging investigations such as CT-scan, bronchoscopy or GI 
endoscopy in the absence of symptoms11. We decided to perform a chest X-ray as well as upper and 
lower GI tract endoscopy before initiating a treatment strategy since single skin lesions can be treated 
locally.  
Independently of any other factor all HIV-infected patients diagnosed with KS should receive ART8. 
Effective antiretroviral regimens reduce the incidence of AIDS-related KS and are associated with 
histological regression of existing lesions in most cases. Limited local disease may be treated with a 
variety of therapies depending on size and location including cryotherapy, laser therapy, radiation and 
intralesional chemotherapy (e.g. vinblastine). Systemic therapies for disseminated disease approved 
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by the FDA include two liposomal anthracyclines (doxorubicin and daunorubicin) and the taxane 
paclitaxel. 
The development of KS in HIV-infected patients with high CD4+ cell count – as seen in our case - is 
rare. While theoretically KS may occur at any stage of HIV infection, to our knowledge so far merely a 
few case reports of KS in patients with high CD4+ cell count were published12. Our case is the first one 
published on the occurrence of KS in a patient effectively treated with early ART since diagnosis of 
primary HIV infection. What triggers the development of KS in patients under successful ART with 
formally normal immune function is still unknown. Increased immune activation may be a possible 
cofactor. As mentioned above, laboratory investigations found signs of immune activation in our 
patient. However, whether KS itself leads to immune activation or vice versa remains unclear.  
The answer to the question why some individuals are able to successfully control persistent HHV-8 
infection and thereby prevent the onset of KS while others are not most likely lies in the HHV-8 
specific immune responses, which are still poorly understood13. Lambert M. et al compared the HHV-8 
specific CD8+ T-cell responses in transplant recipients and HIV-infected patients with and without KS. 
The patients who did not develop KS clearly had more frequent anti-HHV-8 T-cell responses. Since 
the cellular response to Cytomegalovirus, a further latent virus, was similar in both patient groups, the 
author's findings do not seem to reflect global CD8+ dysfunction14. The observations show lower HHV-
8 specific CD8+ T cell response and lower response to HHV-8 specific antigens in patients 
progressing to KS. A study published by the Swiss HIV Cohort Study was able to show that the 
humoral immune response to HHV-8 increases after 24 months of highly active antiretroviral 
treatment (HAART), even in MSM without KS9. This humoral immune response together with changes 
in cellular immunity explains the protection against KS offered by HAART. The occurrence of KS in a 
patient started on HAART during primary HIV infection is even more remarkable since initiation of 
HAART at a very early stage of infection is associated with preserved immune function_ENREF_14. 
One could hypothesize that this fact should have contributed to a sufficient control of latent HHV-8 
infection. 
 
Luckily, KS has become a rare malignancy in the era of ART, at least in developed countries. Today, 
the incidence of KS is less than 10% of the incidence reported in 19944. Nonetheless, by presenting 
this case we would like to emphasize the importance of keeping the possibility of KS in mind even in 
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HIV-infected patients with high CD4+ cell count and on antiretroviral treatment in order not to miss this 
potentially devastating disease. Our patient's case challenges the common perception of KS as an 
AIDS-defining illness in patients with normal CD4+ cell counts. 
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Figure 1: 
                             
A: Left foot, malleolar. Dark brown patchy lesion measuring 3x5mm 
 
B: Glans penis. Dark brown papule measuring 2x2mm 
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Figure 2: 
               
A: Hematoxylin-eosin stain. Dermal tumor consisting of spindle cells with irregular vessel lumina 
formation, plasma cells and erythrocyte extravasates in the tumoral stroma 
 
 
B: HHV-8 stain. Positive HHV-8 immunochemistry staining in spindle cells. 
